This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
22 Apr 2011

EMA: NicOx S.A. Withdraws Its Marketing Authorisation Application for Beprana

The decision to withdraw the application was based on the fact that the CHMP considers that the data provided do not allow the it to conclude on a positive benefit-risk balance.

The European Medicines Agency has been formally notified by NicOx S.A. of its decision to withdraw its application for a centralised marketing authorisation for Beprana (naproxcinod), 375 mg hard capsules, used for the relief of the signs and symptoms of osteoarthritis of the knee and hip in adults.

 

The application for the marketing authorisation for Beprana was initially submitted to the Agency on 21 December 2009. At the time of the withdrawal it was under review by the Agency’s Committee for Medicinal Products for Human Use (CHMP).

 

In its official letter, the company stated that their decision to withdraw the application was based on the fact that the CHMP considers that the data provided do not allo

Related News